Drug
Avutometinib
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | BRAF/MEK Pathway Inhibitors |
| Group | RAF–MEK clamp |
| Mechanism of Action | RAF–MEK clamp |
| Half-life | 51 h |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Expected radiosensitizing on the MEK/BRAF basis (suppressed RAS/RAF/MEK/ERK radioresistance and DNA repair) (Lesperance et al., Advanced Science, 2026). By analogy to BRAF/MEK inhibitors, and because ERK-pathway suppression also affects normal proliferating epithelium, a theoretical increase in in-field cutaneous/visceral adverse events is plausible.
Data on this page refer exclusively to patients treated with
Avutometinib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
RAF–MEK clamp group page.